Most Read Articles
Stephen Padilla, 04 Sep 2019
Use of sodium glucose cotransporter 2 (SGLT2), as compared with dipeptidyl peptidase 4 (DPP4), inhibitors appears to reduce the risk of heart failure and any-cause death without major cardiovascular events in the primary intention-to-treat analysis, according to a study.
Pearl Toh, 04 Sep 2019
More intensive LDL-lowering by adding ezetimibe to simvastatin in elderly individuals aged ≥75 years significantly reduced recurrent cardiovascular (CV) events without raising safety issues compared with simvastatin alone, a secondary analysis of the IMPROVE-IT* has shown.
27 Aug 2019
A once-weekly regimen of 25 mg trelagliptin is effective and safe for type 2 diabetes mellitus (T2DM) patients with severe renal impairment or end-stage renal disease, reports a new study.
Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Oral Xa inhibitors prevent recurrent venous thromboembolism in cancer patients

12 Oct 2018

Oral factor Xa inhibitors may be used as potential substitutes for warfarin and low molecular weight heparin for the prevention of recurrent thromboembolism in oncology patients, suggests a recent study. However, randomized controlled trials are warranted to confirm these results.

A total of 127 patients with venous thromboembolism were recruited, of whom 48 received rivaroxaban or apixaban, 23 received enoxaparin, and 56 received warfarin. Lung (21 percent), colorectal (14 percent) and breast (14 percent) were the three most common cancer diagnoses.

At 3 months, no difference was observed between the rivaroxaban/apixaban (0 percent), warfarin (3.6 percent) and the enoxaparin cohorts (4.4 percent; p=0.8319). Only one patient in the enoxaparin arm (4.2 percent) had a major bleeding at 3 months.

Moreover, mortality was 0 percent, 3.6 percent and 17.4 percent in the rivaroxaban/apixaban, warfarin and enoxaparin cohorts, respectively, at 3 months.

In another study, Xing and colleagues found that rivaroxaban was on a par with enoxaparin in terms of safety and efficacy for the prevention of recurrent venous thromboembolism in patients with malignancy, indicating rivaroxaban as a potential option for cancer patients with venous thromboembolism. [Medicine (Baltimore) 2018;97:e11384]

In this study, the authors used retrospectively obtained data to compare the recurrent venous thromboembolism incidence in oncology patients taking rivaroxaban/apixaban, enoxaparin or warfarin with at least 3 months of follow-up. Inclusion criteria for patients were as follows: active cancer, venous thromboembolism, and taking warfarin, enoxaparin or rivaroxaban/apixaban.

The first episode of recurrent venous thromboembolism at 3 months was the primary endpoint, while the secondary endpoints included recurrent venous thromboembolism after 6 months, major bleeding and mortality.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 04 Sep 2019
Use of sodium glucose cotransporter 2 (SGLT2), as compared with dipeptidyl peptidase 4 (DPP4), inhibitors appears to reduce the risk of heart failure and any-cause death without major cardiovascular events in the primary intention-to-treat analysis, according to a study.
Pearl Toh, 04 Sep 2019
More intensive LDL-lowering by adding ezetimibe to simvastatin in elderly individuals aged ≥75 years significantly reduced recurrent cardiovascular (CV) events without raising safety issues compared with simvastatin alone, a secondary analysis of the IMPROVE-IT* has shown.
27 Aug 2019
A once-weekly regimen of 25 mg trelagliptin is effective and safe for type 2 diabetes mellitus (T2DM) patients with severe renal impairment or end-stage renal disease, reports a new study.
Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.